Drug Trial Radar · NCT02544815
Digoxin Short Term Treatment Assessment Randomized Trial in AHF
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
500
Actual
Start
May 1, 2023
Primary completion
Aug 31, 2026
Study completion Aug 31, 2026
Sponsor
- Lead sponsor
- University of MonastirAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 9, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
AHFS management is challenging and most of the used drugs has failed to decrease post-discharge mortality and readmission rates which represent the most important goal in AHFS. Digoxin processes many characteristics of a beneficial drug for heart failure, however recent publications has rose concerns about its safety profile and therefore decreasing its use. Whether digoxin is efficient and safe in short term treatment of acute heart failure is a question that should be studied.
Conditions
- Acute Heart Failure
Interventions
DigoxinDrug
Digoxin 0.25 mg pills
PlaceboDrug
Placebo pills
Primary outcomes
What the sponsor says the trial is designed to measure.
- 30 days mortality and rehospitalization rateTime frame: 30 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Fattouma Bourguiba University Hospital
Monastir, Tunisia
Sahloul University Hospital
Hammam Sousse, Sousse Governorate, Tunisia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.